Pulse Biosciences CS (PLSE) Stock Price, Quote & News

Company Profile

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment c...

Industry: Medical Instruments & Supplies

Sector: Healthcare

Phone: 510-906-4600

Website: www.pulsebiosciences.com

Address:

601 Brickell Key Drive, Suite 1080, Miami, United States

bob2013 Mar. 20 at 10:59 AM

$PLSE Bio Science is revolutionizing the way they treat AF, this technology is mind blowing. Only foreseeable problem is improving on near perfection?? but take Heart….. (HE KNOWS)!!!

0 · Reply

Doozio Mar. 19 at 11:50 PM

If da chop chop started in oct then keep an $EYE out for da huckleberries wen only da 🐑 remain cuz da 🧠 has a $PLSE 🐒🍌🧠⏰♾️

0 · Reply

Doozio Mar. 19 at 11:27 PM

Da 🧠 has a $PLSE now giddy up ENTA 🐒🍌🧠⏰♾️

0 · Reply

TruthBroker2 Mar. 19 at 12:09 AM

$PLSE He Knows.

0 · Reply

bob2013 Mar. 18 at 4:54 PM

$PLSE company all but said partnership is a done deal!!TBD who??? (HE KNOWS)!!!

0 · Reply

bob2013 Mar. 18 at 9:57 AM

$PLSE The European feasibility data from over 150 patients sends a definitive message,” said Mr. Duggan, Co-Chairman of Pulse Biosciences. “The nPulse clinical performance demonstrates a clear potential to change clinical practice for the health treatment of millions of patients. Our mission to support this program deserves our highest priority, and we are updating our capital allocation to align with this extraordinary opportunity………………… (HE KNOWS)!!!

1 · Reply

TruthBroker2 Mar. 17 at 12:57 PM

$PLSE

0 · Reply

DARKP00L Mar. 17 at 11:06 AM

$PLSE 07:03 on Mar. 17 2026 Pulse Biosciences' Long-Term AFib Clinical Data Demonstrates that Nanosecond Pulsed Field Ablation Delivers Speed, Safety, And Long-Term Durable Efficacy For Atrial Fibrillation (AFib). #tradeideas

0 · Reply

TheTradeXchange Mar. 17 at 11:00 AM

$PLSE Pulse Biosciences Announces Strategic Alignment to Accelerate Cardiac Catheter Program Following Exceptional Long-Term AFib Clinical Data

0 · Reply

TruthBroker2 Mar. 16 at 10:49 AM

$PLSE $SMMT

0 · Reply

Pulse Biosciences Announces Strategic Alignment to Accelerate Cardiac Catheter Program Following Exceptional Long-Term AFib Clinical Data

Mar 12, 2026, 7:00 AM EDT - 9 days ago

Pulse Biosciences, Inc. Announces First Enrollments in Feasibility Study for the Treatment of Malignant Thyroid Tumors with nPulse™ Technology

Mar 9, 2026, 7:00 AM EDT - 12 days ago

Pulse Biosciences Announces Clinical Data From nPulse™ Vybrance™ System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation

Mar 5, 2026, 7:00 AM EST - 16 days ago

Pulse Biosciences to Present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference

Mar 4, 2026, 7:00 AM EST - 17 days ago

Pulse Biosciences' nPulse™ Vybrance™ System to be Featured in Multiple Presentations at the North American Society for Interventional Thyroidology Meeting

Feb 20, 2026, 4:05 PM EST - 4 weeks ago

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 20, 2026, 7:00 AM EST - 4 weeks ago

Pulse Biosciences to Present at the 46th Annual TD Cowen Healthcare Conference

Feb 20, 2026, 2:54 AM EST - 4 weeks ago

Pulse Biosciences, Inc. (PLSE) Q4 2025 Earnings Call Transcript

Feb 19, 2026, 4:05 PM EST - 4 weeks ago

Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2025 Financial Results

Feb 9, 2026, 9:18 AM EST - 5 weeks ago

What's Going With Pulse Biosciences Stock On Monday?

Feb 5, 2026, 7:00 PM EST - 6 weeks ago

Pulse Biosciences Presents Late-Breaking Data from nPulse™ Cardiac Catheter System First-In-Human Feasibility Study at the AF Symposium

Feb 4, 2026, 4:05 PM EST - 6 weeks ago

Pulse Biosciences Schedules Fourth Quarter & Full Year 2025 Financial Results Conference Call for February 19, 2026

Feb 3, 2026, 7:00 AM EST - 6 weeks ago

Pulse Biosciences' nPulse™ Cardiac Catheter to Be Featured in Multiple Presentations at the AF Symposium

Jan 15, 2026, 1:46 AM EST - 2 months ago

Pulse Biosciences, Inc. (PLSE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 9, 2026, 7:00 AM EST - 2 months ago

Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors

Jan 6, 2026, 7:00 AM EST - 2 months ago

Pulse Biosciences Selected to Present Late-Breaking Data from the nPulse Cardiac Catheter Study at the AF Symposium

Dec 29, 2025, 4:05 PM EST - 2 months ago

Pulse Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 18, 2025, 7:00 AM EST - 3 months ago

Pulse Biosciences Announces FDA IDE Approval to Initiate its nPulse Cardiac Catheter Ablation System Study for the Treatment of Atrial Fibrillation

Dec 9, 2025, 7:00 AM EST - 3 months ago

Pulse Biosciences, Inc. Announces Initiation of Research Collaboration for the Treatment of Benign and Malignant Thyroid Tumors with nPulse™ Technology

Nov 6, 2025, 4:05 PM EST - 4 months ago

Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences

Nov 5, 2025, 11:01 PM EST - 4 months ago

Pulse Biosciences, Inc. (PLSE) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 4:05 PM EST - 4 months ago

Pulse Biosciences Reports Business Updates and Third Quarter 2025 Financial Results

Oct 24, 2025, 7:00 AM EDT - 5 months ago

Pulse Biosciences Announces First Enrollment in the NANOCLAMP AF Study

Oct 22, 2025, 4:05 PM EDT - 5 months ago

Pulse Biosciences Schedules Third Quarter 2025 Business Updates and Financial Results Conference Call for November 5, 2025

Oct 10, 2025, 7:00 AM EDT - 5 months ago

Pulse Biosciences Announces Presentation of Late-Breaking Data From the nPulse™ Cardiac Surgical System First-in-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting

Oct 7, 2025, 7:00 AM EDT - 5 months ago

Pulse Biosciences Announces Clinical Data Highlighting its nPulse™ Cardiac Surgical System to be Presented at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting

Sep 10, 2025, 7:00 AM EDT - 6 months ago

Pulse Biosciences' nPulse™ Technology to be Featured at the American Thyroid Association 2025 Annual Meeting

Sep 8, 2025, 7:00 AM EDT - 6 months ago

Pulse Biosciences Announces FDA IDE Approval to Initiate its nsPFA Cardiac Surgery System Study for the Treatment of Atrial Fibrillation

Sep 2, 2025, 7:00 AM EDT - 7 months ago

Pulse Biosciences Announces First Successful Procedures in PRECISE Benign Thyroid Nodule (BTN) Study

Aug 26, 2025, 7:00 AM EDT - 7 months ago

Pulse Biosciences Announces Publication of First-In-Human Data for Treatment of Benign Thyroid Nodules in the Journal Thyroid

Aug 12, 2025, 9:06 PM EDT - 7 months ago

Pulse Biosciences, Inc. (PLSE) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 4:05 PM EDT - 7 months ago

Pulse Biosciences Reports Business Updates and Second Quarter 2025 Financial Results

Aug 1, 2025, 7:00 AM EDT - 8 months ago

Pulse Biosciences To Present at the 45th Canaccord Genuity Annual Growth Conference

Jul 29, 2025, 4:05 PM EDT - 8 months ago

Pulse Biosciences Schedules Second Quarter 2025 Business Updates and Financial Results Conference Call for August 12, 2025

May 10, 2025, 11:02 PM EDT - 11 months ago

Pulse Biosciences, Inc. (PLSE) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:05 PM EDT - 11 months ago

Pulse Biosciences Reports Business Updates and First Quarter 2025 Financial Results

May 6, 2025, 4:05 PM EDT - 11 months ago

Pulse Biosciences To Present at the BofA Securities 2025 Health Care Conference

May 1, 2025, 7:00 AM EDT - 11 months ago

Pulse Biosciences' Nanosecond PFA Technology to be Featured at The American Association for Thoracic Surgery 2025 Annual Meeting

Apr 24, 2025, 4:05 PM EDT - 11 months ago

Pulse Biosciences Schedules First Quarter 2025 Financial Results Conference Call for May 8, 2025

Apr 23, 2025, 7:00 AM EDT - 11 months ago

Pulse Biosciences' Nanosecond PFA Technology to be Featured at The Heart Rhythm Society 2025 Annual Meeting

Mar 27, 2025, 7:46 PM EDT - 1 year ago

Pulse Biosciences, Inc. (PLSE) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 4:05 PM EDT - 1 year ago

Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2024 Financial Results

Mar 26, 2025, 4:05 PM EDT - 1 year ago

Pulse Biosciences To Present at the 24th Annual Needham Virtual Health Care Conference

Mar 7, 2025, 8:00 AM EST - 1 year ago

Pulse Biosciences Schedules Fourth Quarter & Full Year 2024 Financial Results Conference Call for March 27, 2025

Feb 20, 2025, 4:05 PM EST - 1 year ago

Pulse Biosciences To Present at the TD Cowen 45th Annual Health Care Conference

Feb 4, 2025, 8:00 AM EST - 1 year ago

Pulse Biosciences, Inc. Appoints Jon Skinner as Chief Financial Officer

Jan 30, 2025, 8:00 AM EST - 1 year ago

Pulse Biosciences' Nanosecond PFA Technology to Be Featured in Presentations at North American Society for Interventional Thyroidology Annual Meeting

Jan 21, 2025, 7:00 AM EST - 1 year ago

Pulse Biosciences Announces Late-Breaking Data from its Nanosecond PFA 360° Cardiac Catheter System First-In-Human Feasibility Study Presented at the AF Symposium

Jan 13, 2025, 7:00 AM EST - 1 year ago

Pulse Biosciences' Nanosecond PFA Technology to be Featured in Multiple Presentations at the AF Symposium

Jan 10, 2025, 8:00 AM EST - 1 year ago

Pulse Biosciences, Inc. Appoints Paul LaViolette as Chief Executive Officer

bob2013 Mar. 20 at 10:59 AM

$PLSE Bio Science is revolutionizing the way they treat AF, this technology is mind blowing. Only foreseeable problem is improving on near perfection?? but take Heart….. (HE KNOWS)!!!

0 · Reply

Doozio Mar. 19 at 11:50 PM

If da chop chop started in oct then keep an $EYE out for da huckleberries wen only da 🐑 remain cuz da 🧠 has a $PLSE 🐒🍌🧠⏰♾️

0 · Reply

Doozio Mar. 19 at 11:27 PM

Da 🧠 has a $PLSE now giddy up ENTA 🐒🍌🧠⏰♾️

0 · Reply

TruthBroker2 Mar. 19 at 12:09 AM

$PLSE He Knows.

0 · Reply

bob2013 Mar. 18 at 4:54 PM

$PLSE company all but said partnership is a done deal!!TBD who??? (HE KNOWS)!!!

0 · Reply

bob2013 Mar. 18 at 9:57 AM

1 · Reply

TruthBroker2 Mar. 17 at 12:57 PM

$PLSE

0 · Reply

DARKP00L Mar. 17 at 11:06 AM

0 · Reply

TheTradeXchange Mar. 17 at 11:00 AM

$PLSE Pulse Biosciences Announces Strategic Alignment to Accelerate Cardiac Catheter Program Following Exceptional Long-Term AFib Clinical Data

0 · Reply

TruthBroker2 Mar. 16 at 10:49 AM

$PLSE $SMMT

0 · Reply

TruthBroker2 Mar. 13 at 4:21 PM

$PLSE

0 · Reply

TruthBroker2 Mar. 13 at 1:30 PM

$SMMT $PLSE

0 · Reply

LeisureSuitLarry Mar. 12 at 4:53 PM

$PLSE

0 · Reply

BubbaHoTep Mar. 12 at 3:42 PM

$PLSE happening

0 · Reply

TruthBroker2 Mar. 12 at 2:52 PM

$PLSE We got a runner. HE KNOWS. Team Pulse

0 · Reply

bob2013 Mar. 12 at 12:14 PM

$PLSE our mission to rigorously generate data and demonstrate the potential to improve patient outcomes and provide clinicians with more precise, tissue-sparing tools for minimally invasive treatment applications.” (HE KNOWS)!!!

0 · Reply

DARKP00L Mar. 12 at 11:07 AM

$PLSE 07:06 on Mar. 12 2026 Pulse Biosciences Begins First Human Study Of New Device To Treat Small Thyroid Cancer Tumors #tradeideas

0 · Reply

TheTradeXchange Mar. 12 at 11:00 AM

$PLSE Pulse Biosciences, Inc. Announces First Enrollments in Feasibility Study for the Treatment of Malignant Thyroid Tumors with nPulse™ Technology

0 · Reply

TruthBroker2 Mar. 10 at 6:56 PM

$PLSE

0 · Reply

TruthBroker2 Mar. 10 at 3:50 PM

$PLSE Team Pulse

0 · Reply

BubbaHoTep Mar. 9 at 2:44 PM

https://www.businesswire.com/news/home/20260309737760/en/ $PLSE

0 · Reply

TheTradeXchange Mar. 9 at 11:01 AM

$PLSE Pulse Biosciences Announces Clinical Data From nPulse™ Vybrance™ System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation

0 · Reply

Market Cap	1.50B
Revenue (ttm)	350,000.00
Net Income (ttm)	-72.78M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-20,794.29%
Debt to Equity Ratio	0.00

Volume	335,700
Avg Vol	364,460
Day's Range	N/A - N/A
Shares Out	67.99M
Stochastic %K	79%
Beta	1.74
Analysts	Strong Sell
Price Target	$30.00